1. MATERIALS & METHODS BACKGROUND RESULTS OBJECTIVES SUMMARY
Table (4):- Incidence of portal vein thrombosis.
Role of Low Molecular Weight Heparins (LMWH) in Prevention of Thromboembolic Complication After Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma.
Osama Negm 1, Sabry Abou Saif 1, Mohamed El Gharib 2, Mohamed Yousef 1, Sherief Abd-Elsalam 1.
MATERIALS & METHODS
BACKGROUND
RESULTS
Please export the Keynote document as a PDF (File – Save as – PDF – Image Quality – Best) and upload the PDF into the system. Please use the font in the document or a similar one and do not use a font size smaller than 16.
This study was conducted on 40 patients with HCC requiring Transarterial chemoembolization who presented to the Tropical Medicine Department Tanta University and Interventional Radiology. The incidence of portal vein thrombosis after TACE was more in group I than group II with Seven cases in group I & only one case in group II.
Portal vein thrombosis is a common complication after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC).
This study was conducted on 40 patients with HCC requiring Transarterial chemoembolization who presented to the Tropical Medicine Department Tanta University and Interventional Radiology Department of Ain Shams University Hospitals starting from April 2015.
OBJECTIVES
PVT
Group
Group I
Group II
Total N %
Negative 13
65.00 19
95.00 32
85.00
Positive 7
35.00 1
5.00 8
15.00
Chi- squar e X2
3.906
P- value
0.048
Patients were divided in two groups:
Group I: included 20 patients with HCC treated by TACE only.
Group II: included 20 patients with HCC treated by TACE and adjuvant dose of LMWH.
Radiological Assessment of efficacy of procedure and detection of portal vein thrombosis as a complication was done using ultrasound abdomen and pelvis and triphasic spiral C T with contrast.
This is the first clinical study to evaluate the role of low molecular weight heparins (LMWH) with TACE in HCC for prevention of thromboembolism complications (portal vein thrombosis).
SUMMARY
LMWH with TACE in hepatocellular carcinoma is strongly recommended for prevention of thromboembolism complications (portal vein thrombosis). However, larger randomized controlled studies are needed to confirm these obvious findings.
Table (1):- Incidence of portal vein thrombosis.
Contact information:
LMWH with TACE in hepatocellular carcinoma is strongly recommended for prevention of thromboembolism complications (portal vein thrombosis). However, larger randomized controlled studies are needed to confirm these obvious findings.